DPI 125
Alternative Names: DPI-125; MCP-201Latest Information Update: 17 Nov 2023
At a glance
- Originator Enhance Biotech
- Developer DMK Pharmaceuticals
- Class Analgesics; Phenols; Piperazines; Small molecules; Thiophenes
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Opioid-related disorders; Pain
Most Recent Events
- 13 Nov 2023 Pharmacodynamics data from preclinical trials in Opioid-related disorders presented at the Society for Neuroscience Annual Meeting (SfN-2023)
- 17 Mar 2023 Chemical structure information added
- 28 Feb 2023 DPI 125 is still in phase I trial for Pain in USA (DMK pharmaceutical pipeline, February 2023)